Pre-anesthetic use of butorphanol for the prevention of emergence agitation in thoracic surgery: A multicenter, randomized controlled trial

Tao Meng, Xiaowen Lin, Ximing Li, Fangli Yue, Yuzhu Zhang, Yingbin Wang, Jianhua Gu, Zaiqi Yang, Hongli Yu, Kun Lv, Shengyong Liang, Xingda Li, Zhu Weibo, Gang Yu, Tao Li, Yujia Ren, Yandong Li, Jianjun Xu, Weimin Xu, Shu Wang, Jianbo WuFrontiers in Medicine 2022 · DOI

TL;DR

This multicenter randomized controlled trial investigated the effectiveness of pre-anesthetic butorphanol in preventing emergence agitation (EA) in patients undergoing thoracic surgery. The study found that a single dose of butorphanol significantly reduced the incidence of EA and associated complications, offering a promising strategy for improving post-anesthesia recovery.

What Problem Does This Paper Address?

Emergence agitation (EA) is a common and potentially problematic complication following general anesthesia (GA), characterized by confusion, disorientation, and restless behavior. This can lead to adverse outcomes like falls, dislodged medical devices, and increased healthcare costs. Patients undergoing thoracic surgery are particularly susceptible to EA due to the nature of the surgery, which often involves significant trauma and the use of chest drainage tubes. While various interventions have been explored to mitigate EA, there's a continuous need for effective and safe preventative measures, especially for high-risk patient populations. This paper specifically addresses the gap in understanding the efficacy of pre-anesthetic butorphanol, a lesser-studied opioid in this context, for preventing EA in thoracic surgery patients.

Methods

This study employed a prospective, randomized, allocation-concealed, open-label, parallel-group, multicenter trial design. The research was conducted across 20 hospitals in eastern China. A total of 620 patients undergoing elective video-assisted thoracoscopic lobectomy/segmentectomy for lung cancer were enrolled. Participants were randomly assigned in a 1:1 ratio to receive either butorphanol (0.02 mg/kg, diluted in 10 ml saline, injected slowly over 1 minute, 15 minutes before GA induction) or a volume-matched placebo (saline).

The primary outcome measured was the incidence of EA at 5 minutes post-extubation, defined as a Riker Sedation-Agitation Scale (RSAS) score greater than 4. Secondary outcomes included Ramsay scores, Numerical Rating Scale (NRS) pain scores, intraoperative anesthetic consumption, and the incidence of drug-related complications (e.g., propofol injection pain, coughing with sufentanil). Statistical analysis involved chi-square tests for categorical data and t-tests or Mann-Whitney U-tests for continuous data, with a significance level set at P < 0.05.

Datasets

Not discussed in the paper. The study utilized patient data collected during the clinical trial.

Key Insights and Ideas

  • Butorphanol as a Pre-anesthetic EA Preventative: The study highlights butorphanol, an opioid agonist-antagonist, as a viable option for preventing EA, moving beyond more commonly studied agents.
  • Thoracic Surgery Specifics: The focus on thoracic surgery patients underscores the importance of tailored strategies for populations with higher EA risk.
  • Reduced Complications: The significant reduction in drug-related complications, beyond just EA, suggests a broader benefit of pre-anesthetic butorphanol.
  • Potential for Improved Patient Comfort: Lower pain scores and Ramsay scores in the butorphanol group indicate a potentially smoother and more comfortable emergence from anesthesia.

Key Results

The study found a statistically significant reduction in the incidence of emergence agitation (EA) in the butorphanol group compared to the control group.

  • Incidence of EA: 9.8% (29 of 296) in the butorphanol group vs. 24.5% (75 of 306) in the control group (P = 0.0001).
  • Drug-Related Complications:
    • Propofol injection pain: 37.8% (112 of 296) in the butorphanol group vs. 65% (199 of 306) in the control group (P = 0.001).
  • Coughing with sufentanil injection: 1% (3 of 296) in the butorphanol group vs. 11.4% (35 of 306) in the control group (P = 0.0001).
  • Pain Scores: NRS scores at radial artery catheter placement, 5 minutes post-extubation, and 15 minutes post-PACU arrival were significantly lower in the butorphanol group.
  • Ramsay Scores: Ramsay scores at 5 minutes post-butorphanol administration were significantly different between the groups (P = 0.0001).
  • Rescue Analgesia: A lower requirement for rescue analgesia was observed in the butorphanol group (4.7% vs. 7.5%, P = 0.042).

Limitations and Future Work

The authors acknowledge several limitations:

  • Primary Outcome Focus: The study primarily focused on EA, and further research is needed to assess the effect of pre-anesthetic butorphanol on long-term outcomes.
  • Anesthesiologist Variability: The involvement of over 40 anesthesiologists across multiple centers could introduce variability in anesthesia and surgical quality.
  • Blinding Challenges: Due to the nature of the intervention, blinding of treatment was not fully possible, as 34% of patients in the butorphanol group showed sedation before surgery. However, clinical outcome scoring was performed by blinded assessors.

Future work should investigate the long-term effects of pre-anesthetic butorphanol and explore its efficacy in other surgical populations or with different administration protocols.

Summary updated

Abstract

[http://www.chictr.org.cn/showproj.aspx?proj=42684], identifier [ChiCTR1900025705].
BibTeX
@inproceedings{meng2022pre,
  author = {Tao Meng and Xiaowen Lin and Ximing Li and Fangli Yue and Yuzhu Zhang and Yingbin Wang and Jianhua Gu and Zaiqi Yang and Hongli Yu and Kun Lv and Shengyong Liang and Xingda Li and Zhu Weibo and Gang Yu and Tao Li and Yujia Ren and Yandong Li and Jianjun Xu and Weimin Xu and Shu Wang and Jianbo Wu},
  title = {{Pre-anesthetic use of butorphanol for the prevention of emergence agitation in thoracic surgery: A multicenter, randomized controlled trial}},
  booktitle = {Frontiers in Medicine},
  year = {2022},
  doi = {10.3389/fmed.2022.1040168},
}
Figure